Scilex Pursues Major Bitcoin Acquisition via Term Sheet
TipRanks (Mon, 29-Jun 5:31 PM ET)
PRNewswire (Thu, 25-Jun 11:35 AM ET)
Scilex Stockholders Approve Director Election and Equity Plan
TipRanks (Wed, 24-Jun 5:18 PM ET)
Scilex to List Dream Bowl I Meme Coin on Biconomy—Liquidity Opportunity for Shareholders Looms
Market Chameleon (Tue, 16-Jun 3:47 AM ET)
Globe Newswire (Tue, 16-Jun 7:45 AM ET)
Globe Newswire (Fri, 12-Jun 7:53 AM ET)
Globe Newswire (Thu, 4-Jun 9:00 AM ET)
Globe Newswire (Fri, 22-May 1:15 PM ET)
Business Wire (Wed, 20-May 9:11 AM ET)
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Scilex Holding Company trades on the NASDAQ stock market under the symbol SCLX.
As of June 29, 2026, SCLX stock price climbed to $7.80 with 48,076 million shares trading.
SCLX has a beta of 1.53, meaning it tends to be more sensitive to market movements. SCLX has a correlation of 0.02 to the broad based SPY ETF.
SCLX has a market cap of $54.86 million. This is considered a Micro Cap stock.
In the last 3 years, SCLX traded as high as $233.80 and as low as $3.60.
The top ETF exchange traded funds that SCLX belongs to (by Net Assets): VTI, VXF, IWC, ITOT, AVTM.
SCLX has outperformed the market in the last year with a return of +47.2%, while the SPY ETF gained +22.3%. In the last 3 month period, SCLX beat the market returning +18.5%, while SPY returned +15.2%. However, in the most recent 2 weeks SCLX has underperformed the stock market by returning -8.2%, while SPY returned +0.2%.
SCLX support price is $6.39 and resistance is $7.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SCLX shares will trade within this expected range on the day.
